Shots: The P-III COMBI-AD study involves assessing of Tafinlar (dabrafenib, 150mg, bid) + Mekinist (trametinib, 2mg, qd) vs two PBOs in patients with stage III, BRAF V600E/K-mutant melanoma without prior […]readmore
Tags : Stage III Melanoma
Shots: The approval is based on P-III EORTC1325/KEYNOTE-054 trial assessing Keytruda (IV 200mg, q3w) as adjuvant therapy vs PBO, in 1,019 patients in ratio (1:1) with completely resected melanoma (stage IIIA [>1 mm […]readmore